Equities Analysts Offer Predictions for ZNTL Q1 Earnings

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Stock analysts at Leerink Partnrs dropped their Q1 2025 earnings estimates for Zentalis Pharmaceuticals in a research note issued on Wednesday, March 26th. Leerink Partnrs analyst A. Berens now expects that the company will post earnings per share of ($0.69) for the quarter, down from their prior forecast of ($0.68). The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.42) per share. Leerink Partnrs also issued estimates for Zentalis Pharmaceuticals’ FY2025 earnings at ($2.01) EPS and FY2026 earnings at ($1.82) EPS.

Several other brokerages also recently commented on ZNTL. UBS Group dropped their target price on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Wells Fargo & Company dropped their price objective on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating on the stock in a report on Thursday, January 30th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Zentalis Pharmaceuticals in a research note on Thursday. Finally, Wedbush reissued a “neutral” rating and issued a $4.00 price target on shares of Zentalis Pharmaceuticals in a research note on Friday. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $8.24.

Zentalis Pharmaceuticals Price Performance

NASDAQ:ZNTL opened at $1.81 on Monday. The business’s 50-day simple moving average is $2.04 and its 200-day simple moving average is $2.85. Zentalis Pharmaceuticals has a fifty-two week low of $1.61 and a fifty-two week high of $16.27. The stock has a market capitalization of $129.98 million, a PE ratio of -0.73 and a beta of 1.75.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its earnings results on Wednesday, March 26th. The company reported ($0.66) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.09. The business had revenue of $26.90 million for the quarter.

Insider Activity

In other news, insider Ingmar Bruns acquired 20,000 shares of the firm’s stock in a transaction dated Thursday, February 6th. The stock was bought at an average price of $2.28 per share, with a total value of $45,600.00. Following the transaction, the insider now directly owns 36,629 shares in the company, valued at approximately $83,514.12. The trade was a 120.27 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Jan Skvarka bought 60,000 shares of the company’s stock in a transaction dated Friday, January 31st. The stock was purchased at an average cost of $1.72 per share, for a total transaction of $103,200.00. Following the completion of the acquisition, the director now owns 149,551 shares in the company, valued at $257,227.72. This trade represents a 67.00 % increase in their position. The disclosure for this purchase can be found here. 3.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the business. Wealth Enhancement Advisory Services LLC lifted its position in shares of Zentalis Pharmaceuticals by 194.7% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 200,113 shares of the company’s stock valued at $606,000 after buying an additional 132,220 shares during the last quarter. Vident Advisory LLC acquired a new stake in Zentalis Pharmaceuticals during the 4th quarter valued at $45,000. State of Wyoming increased its holdings in shares of Zentalis Pharmaceuticals by 124.6% in the fourth quarter. State of Wyoming now owns 34,716 shares of the company’s stock valued at $105,000 after purchasing an additional 19,262 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Zentalis Pharmaceuticals in the fourth quarter valued at about $52,000. Finally, Nuveen Asset Management LLC lifted its stake in shares of Zentalis Pharmaceuticals by 35.2% during the 4th quarter. Nuveen Asset Management LLC now owns 641,407 shares of the company’s stock worth $1,943,000 after buying an additional 167,062 shares during the last quarter.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.